纯合子家族性高胆固醇血症的诊断、治疗及心血管结局的性别差异
本研究基于HICC注册登记(38国88家机构)的389例女性和362例男性HoFH患者,回顾性分析发现男女诊断年龄、未治疗LDL-C水平及降脂治疗相似,但女性心肌梗死患病率较低(8.0% vs 16.3%),诊断后16年女性心肌梗死累积发生率显著低于男性(5.0% vs 13.7%;SHR 0.37;95%CI 0.21-0.66),全因和心血管死亡无显著差异。
要点
- HoFH男女诊断年龄和未治疗LDL-C水平相似,与HeFH的性别差异不同。
- 女性心肌梗死患病率较低,但首次心肌梗死年龄与男性相似(39岁 vs 38岁)。
- 诊断后16年女性心肌梗死累积发生率显著低于男性,死亡风险无显著差异。
核心结论
- 在已知HoFH患者中,男性心肌梗死患病率高于女性,但诊断年龄和首次ASCVD事件年龄相似。
- 早期诊断和治疗对减轻两性过高的心血管风险均重要。
研究设计与样本
- 回顾性队列研究,纳入HICC注册登记中2010年及以后存活的HoFH患者,共389例女性和362例男性,来自38个国家88家机构。
主要发现
- 男女诊断年龄相似(中位数13岁 vs 11岁),未治疗LDL-C水平相似(均值579 mg/dL vs 596 mg/dL)。
- 吸烟比例女性14.3%(38/266)低于男性27.2%(59/217),其他心血管危险因素患病率相似。
- 心肌梗死患病率女性8.0%(31/389)低于男性16.3%(59/362),首次心肌梗死年龄相似(39岁 vs 38岁)。
- 他汀使用率女性89.9%(248/276)与男性91.1%(235/258)相似,脂蛋白血浆置换率女性36.3%(115/317)与男性38.8%(118/304)相似。
- 诊断后16年,女性心肌梗死累积发生率5.0%显著低于男性13.7%(SHR 0.37;95%CI 0.21-0.66),全因死亡(3.0% vs 4.1%;HR 0.76;95%CI 0.40-1.45)和心血管死亡(2.6% vs 4.1%;SHR 0.87;95%CI 0.44-1.75)无显著差异。
临床怎么用
- 对HoFH患者应强调早期诊断和早期启动降脂治疗,以减轻两性过高的心血管风险。
- 男性HoFH患者心肌梗死风险更高,需加强监测和危险因素管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Homozygous familial hypercholesterolemia (HoFH) is a rare genetic condition characterized by extremely increased low-density lipoprotein (LDL) cholesterol levels and premature atherosclerotic cardiovascular disease (ASCVD). Heterozygous familial hypercholesterolemia (HeFH) is more common than HoFH, and women with HeFH are diagnosed later and undertreated compared to men; it is unknown whether these sex differences also apply to HoFH. OBJECTIVE: To investigate sex differences in age at diagnosis, risk factors, lipid-lowering treatment, and ASCVD morbidity and mortality in patients with HoFH. DESIGN, SETTING, AND PARTICIPANTS: Sex-specific analyses for this retrospective cohort study were performed using data from the HoFH International Clinical Collaborators (HICC) registry, the largest global dataset of patients with HoFH, spanning 88 institutions across 38 countries. Patients with HoFH who were alive during or after 2010 were eligible for inclusion. Data entry occurred between February 2016 and December 2020. Data were analyzed from June 2022 to June 2023. MAIN OUTCOMES AND MEASURES: Comparison between women and men with HoFH regarding age at diagnosis, presence of risk factors, lipid-lowering treatment, prevalence, and onset and incidence of ASCVD morbidity (myocardial infarction [MI], aortic stenosis, and combined ASCVD outcomes) and mortality. RESULTS: Data from 389 women and 362 men with HoFH from 38 countries were included. Women and men had similar age at diagnosis (median [IQR], 13 [6-26] years vs 11 [5-27] years, respectively), untreated LDL cholesterol levels (mean [SD], 579 [203] vs 596 [186] mg/dL, respectively), and cardiovascular risk factor prevalence, except smoking (38 of 266 women [14.3%] vs 59 of 217 men [27.2%], respectively). Prevalence of MI was lower in women (31 of 389 [8.0%]) than men (59 of 362 [16.3%]), but age at first MI was similar (mean [SD], 39 [13] years in women vs 38 [13] years in men). Treated LDL cholesterol levels and lipid-lowering therapy were similar in both sexes, in particular statins (248 of 276 women [89.9%] vs 235 of 258 men [91.1%]) and lipoprotein apheresis (115 of 317 women [36.3%] vs 118 of 304 men [38.8%]). Sixteen years after HoFH diagnosis, women had statistically significant lower cumulative incidence of MI (5.0% in women vs 13.7% in men; subdistribution hazard ratio [SHR], 0.37; 95% CI, 0.21-0.66) and nonsignificantly lower all-cause mortality (3.0% in women vs 4.1% in men; HR, 0.76; 95% CI, 0.40-1.45) and cardiovascular mortality (2.6% in women vs 4.1% in men; SHR, 0.87; 95% CI, 0.44-1.75). CONCLUSIONS AND RELEVANCE: In this cohort study of individuals with known HoFH, MI was higher in men compared with women yet age at diagnosis and at first ASCVD event were similar. These findings suggest that early diagnosis and treatment are important in attenuating the excessive cardiovascular risk in both sexes.
引用
- Mulder JWCM, Tromp TR, Al-Khnifsawi M, et al. Sex Differences in Diagnosis, Treatment, and Cardiovascular Outcomes in Homozygous Familial Hypercholesterolemia. JAMA Cardiol. 2024. PMID: 38353972. doi:10.1001/jamacardio.2023.5597
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。